Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Stasis"

19 News Found

FDA Granted ODD to Utidelone Injectable from Biostar Pharma for treatment of breast cancer brain metastasis
Drug Approval | April 01, 2024

FDA Granted ODD to Utidelone Injectable from Biostar Pharma for treatment of breast cancer brain metastasis

Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux


Merck’s pembrolizumab demonstrates improvement in distant metastasis
News | June 06, 2022

Merck’s pembrolizumab demonstrates improvement in distant metastasis

Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).


USFDA approves first generic of Restasis
Drug Approval | February 03, 2022

USFDA approves first generic of Restasis

Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug


Medtronic partners with Stasis to enhance patient monitoring in India
Digitisation | September 02, 2021

Medtronic partners with Stasis to enhance patient monitoring in India

The Stasis connected care monitoring system includes - a bedside monitor that monitors 6 vital signs, a tablet that enables intuitive monitoring, and the Stasis app that allows for remote monitoring across devices


Pfizer and Astellas' XTANDI approved by USFDA in earlier prostate cancer treatment setting
Drug Approval | November 17, 2023

Pfizer and Astellas' XTANDI approved by USFDA in earlier prostate cancer treatment setting

XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer


Lynparza plus abi/pred approved in Japan for treatment of prostate cancer
Drug Approval | August 25, 2023

Lynparza plus abi/pred approved in Japan for treatment of prostate cancer

First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent


Zion Pharma inks agreement with Roche to develop and commercialize brain-penetrable compounds
News | May 10, 2023

Zion Pharma inks agreement with Roche to develop and commercialize brain-penetrable compounds

ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer


Brain Cells are starved of energy when autophagy malfunctions: New Study
News | May 05, 2023

Brain Cells are starved of energy when autophagy malfunctions: New Study

The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments


Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian
Diagnostic Center | September 01, 2022

Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke


LintonPharm to release data on Catumaxomab at ASCO meeting
Biotech | May 30, 2022

LintonPharm to release data on Catumaxomab at ASCO meeting

The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis